The value of the Australian life science sector declined 3.5 per cent during the fourth quarter, ending 30 June 2006, according to the latest BioForum report from PricewaterhouseCoopers (PwC).

The ASX has issued a 'please explain' to Brisbane-based Analytica (ASX:ALT), querying whether the company will have enough cash to last it past the next quarter.

Psiron (ASX:PSX) has moved to reassure shareholders of its ability to fund its business plans, in the wake of last week's resignations of the company's CEO and CFO.

Julie Nutting has stepped down as both CEO and director of Sydney-based Psiron (ASX:PSX), positions she has held since December 2003.

Adelaide biotechnology manufacturer BresaGen (ASX:BGN) has executed supply contracts worth AUD$680,000 with WA based junior biotech Caldeon and Brisbane's Tissue Therapies (ASX:TIS).

Sydney oncology therapy developer Psiron (ASX:PSX) has received orphan drug designation from the US Food and Drug Administration (FDA) for its lead oncolytic virus Cavatak (coxsackievirus A21) for the treatment of stage II, stage III and stage IV melanoma.

The Berlin-Bremen stock exchange in Germany has advised Psiron (ASX:PSX) that a third party has applied for the Sydney-based oncology therapy developer's shares to be listed on Freiverkehr, the stock exchange's third market segment.

Sydney biotech Psiron (ASX:PSX) will be the first client for rejuvenated Adelaide biotechnology manufacturer BresaGen's new pilot production plant for therapeutics produced in mammalian cell cultures.

PharmAust (ASX:PAA) has appointed Dr Paul D'Sylva as managing director, also making him responsible for the company's wholly owned subsidiary companies Epichem, Mimotopes and PharmAust Manufacturing.

Sydney oncology therapy developer Psiron (ASX:PSX) has announced a delay in reporting the results of its first phase I clinical trial of its cancer-slaying CVA 21 viral therapy in melanoma patients because of delays in access to supplies of the virus.

Acrux (ASX:ACR) has received a US$1 million milestone payment from Vivus for its estradiol transdermal spray product Evamist, currently in Phase III clinical trials to treat menopausal symptoms in the US, which was due today.